Some determinants of the therapeutic efficacy of actinomycin D (NSC-3053), adriamycin (NSC-123127), and daunorubicin (NSC-83142).
D000818:Animals; D002250:Carbon Radioisotopes; D004273:DNA, Neoplasm / Q000378:metabolism; D003609:Dactinomycin / Q000378:metabolism / Q000627:therapeutic use*; D003630:Daunorubicin / Q000378:metabolism / Q000627:therapeutic use*; D004317:Doxorubicin / Q000378:metabolism / Q000627:therapeutic use*; D007421:Intestine, Small / Q000378:metabolism; D007700:Kinetics; D007939:Leukemia L1210 / Q000188:drug therapy; D008727:Methotrexate / Q000627:therapeutic use; D051379:Mice; D008806:Mice, Inbred AKR; D009368:Neoplasm Transplantation; D009374:Neoplasms, Experimental / Q000188:drug therapy; D012516:Osteosarcoma / Q000188:drug therapy; D013936:Thymidine / Q000378:metabolism; D013997:Time Factors; D014184:Transplantation, Homologous; D014316:Tritium
D002250:Carbon Radioisotopes; D004273:DNA, Neoplasm; D014316:Tritium; D003609:Dactinomycin; D004317:Doxorubicin; D013936:Thymidine; D008727:Methotrexate; D003630:Daunorubicin